ProMIS Neurosciences, Inc. (TSE:PMN – Get Free Report) shares traded down 3.8% during trading on Monday . The stock traded as low as C$5.98 and last traded at C$6.00. 19,701 shares changed hands during trading, an increase of 492% from the average session volume of 3,327 shares. The stock had previously closed at C$6.24.
ProMIS Neurosciences Price Performance
The company has a debt-to-equity ratio of 108.33, a quick ratio of 1.30 and a current ratio of 0.51. The company’s 50-day moving average price is C$6.00. The stock has a market cap of C$51.48 million, a PE ratio of -1.78 and a beta of 1.19.
ProMIS Neurosciences Company Profile
ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
Featured Stories
- Five stocks we like better than ProMIS Neurosciences
- How to Read Stock Charts for Beginners
- Is Monolithic Power Systems a Screaming Buy After Near 40% Drop?
- What Do S&P 500 Stocks Tell Investors About the Market?
- Applied Materials Market Capitulates: Now is the Time to Buy
- Consumer Discretionary Stocks Explained
- 3 Ultra-High Dividend Yield Stocks for the New Year
Receive News & Ratings for ProMIS Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMIS Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
